

Matthias Griese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7235373/publications.pdf>

Version: 2024-02-01

166
papers

9,628
citations

57631

44
h-index

43802

91
g-index

169
all docs

169
docs citations

169
times ranked

10641
citing authors

#	ARTICLE	IF	CITATIONS
1	A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation. <i>New England Journal of Medicine</i> , 2011, 365, 1663-1672.	13.9	1,920
2	The Human Phenotype Ontology in 2021. <i>Nucleic Acids Research</i> , 2021, 49, D1207-D1217.	6.5	652
3	Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. <i>Nature Biotechnology</i> , 2011, 29, 154-157.	9.4	622
4	Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. <i>Nature Medicine</i> , 2007, 13, 1423-1430.	15.2	291
5	Pulmonary alveolar proteinosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 16.	18.1	244
6	Mutations in CCNO result in congenital mucociliary clearance disorder with reduced generation of multiple motile cilia. <i>Nature Genetics</i> , 2014, 46, 646-651.	9.4	232
7	European protocols for the diagnosis and initial treatment of interstitial lung disease in children. <i>Thorax</i> , 2015, 70, 1078-1084.	2.7	192
8	Pulmonary TH2 response in <i>Pseudomonas aeruginosa</i> -infected patients with cystic fibrosis. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 204-211.	1.5	172
9	Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 719-725.	2.5	154
10	Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and <i>F508del</i> / <i>F508del</i> -CFTR or <i>F508del</i> / <i>G551D</i> -CFTR. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 214-224.	2.5	152
11	Alteration of the Pulmonary Surfactant System in Full-Term Infants with Hereditary ABCA3 Deficiency. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 571-580.	2.5	140
12	Pulmonary complications after bone marrow transplantation in children: Twenty-four years of experience in a single pediatric center. <i>Pediatric Pulmonology</i> , 2000, 30, 393-401.	1.0	128
13	Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. <i>American Journal of Medical Genetics Part A</i> , 2004, 126A, 18-26.	2.4	121
14	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More <i>F508del</i> Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 381-385.	2.5	116
15	In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. <i>Nature Biotechnology</i> , 2015, 33, 584-586.	9.4	113
16	Lung disease caused by <i>ABCA3</i> mutations. <i>Thorax</i> , 2017, 72, 213-220.	2.7	110
17	Improvement of Alveolar Glutathione and Lung Function but Not Oxidative State in Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 822-828.	2.5	104
18	A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. <i>Respiratory Research</i> , 2014, 15, 43.	1.4	100

#	ARTICLE	IF	CITATIONS
19	Free DNA in Cystic Fibrosis Airway Fluids Correlates with Airflow Obstruction. Mediators of Inflammation, 2015, 2015, 1-11.	1.4	100
20	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet Journal of Rare Diseases, 2016, 11, 115.	1.2	100
21	Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients. Respiratory Medicine, 2011, 105, 1908-1916.	1.3	98
22	Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany. Orphanet Journal of Rare Diseases, 2009, 4, 26.	1.2	96
23	Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on RÅ©union Island. American Journal of Human Genetics, 2015, 96, 826-831.	2.6	94
24	Surfactant Protein A and D Differently Regulate the Immune Response to NonmucoidPseudomonas aeruginosaand Its Lipopolysaccharide. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 249-256.	1.4	88
25	TLR Expression on Neutrophils at the Pulmonary Site of Infection: TLR1/TLR2-Mediated Up-Regulation of TLR5 Expression in Cystic Fibrosis Lung Disease. Journal of Immunology, 2008, 181, 2753-2763.	0.4	86
26	Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. Respiratory Research, 2011, 12, 4.	1.4	83
27	Comprehensive genotyping and clinical characterisation reveal 27 novel NKX2-1 mutations and expand the phenotypic spectrum. Journal of Medical Genetics, 2014, 51, 375-387.	1.5	77
28	Phenotype characterisation of <i>TBX4</i> mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. European Respiratory Journal, 2019, 54, 1801965.	3.1	77
29	Pulmonary Surfactant, Lung Function, and Endobronchial Inflammation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1000-1005.	2.5	73
30	Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis. A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 83-89.	2.5	73
31	Protein pattern of exhaled breath condensate and saliva. Proteomics, 2002, 2, 690-696.	1.3	72
32	The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood, 2013, 121, 2943-2951.	0.6	72
33	Genotype alone does not predict the clinical course of<i>SFTPC</i> deficiency in paediatric patients. European Respiratory Journal, 2015, 46, 197-206.	3.1	72
34	International management platform for childrenâ€™s interstitial lung disease (chILD-EU). Thorax, 2018, 73, 231-239.	2.7	64
35	GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulmonary Medicine, 2015, 15, 87.	0.8	63
36	Microbial colonization and lung function in adolescents with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 340-349.	0.3	63

#	ARTICLE	IF	CITATIONS
37	Characterization of CSF2RA mutation related juvenile pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2014, 9, 171.	1.2	61
38	Oxidative Changes of Bronchoalveolar Proteins in Cystic Fibrosis. Chest, 2006, 129, 431-437.	0.4	57
39	Surfactant Proteins A and D in Children with Pulmonary Disease due to Gastroesophageal Reflux. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1546-1550.	2.5	56
40	Interstitial lung disease in children – genetic background and associated phenotypes. Respiratory Research, 2005, 6, 32.	1.4	51
41	Persistent Tachypnea of Infancy. Usual and Aberrant. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 438-447.	2.5	51
42	Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled α 1-protease inhibitor in cystic fibrosis. Electrophoresis, 2001, 22, 165-171.	1.3	50
43	Chronic interstitial lung disease in children. European Respiratory Review, 2018, 27, 170100.	3.0	50
44	Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatric Pulmonology, 2015, 50, 410-419.	1.0	49
45	CompoundSFTPB 1549C>GAA (121ins2) and 457delC heterozygosity in severe congenital lung disease and surfactant protein B (SP-B) deficiency. , 1999, 14, 502-509.		48
46	Analysis of 40 sporadic or familial neonatal and pediatric cases with severe unexplained respiratory distress: Relationship toSFTPB. American Journal of Medical Genetics Part A, 2003, 119A, 324-339.	2.4	47
47	Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. Pediatrics, 2017, 140, e20170610.	1.0	45
48	Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. BMC Pulmonary Medicine, 2018, 18, 79.	0.8	43
49	Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases. Respiratory Research, 2010, 11, 32.	1.4	42
50	Categorizing diffuse parenchymal lung disease in children. Orphanet Journal of Rare Diseases, 2015, 10, 122.	1.2	42
51	Respiratory Syncytial Virus and Pulmonary Surfactant. Viral Immunology, 2002, 15, 357-363.	0.6	40
52	Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency. Journal of Allergy and Clinical Immunology, 2021, 148, 381-393.	1.5	40
53	Hypersensitivity pneumonitis: lessons for diagnosis and treatment of a rare entity in children. Orphanet Journal of Rare Diseases, 2013, 8, 121.	1.2	39
54	Postinfectious Bronchiolitis Obliterans in Children: Diagnostic Workup and Therapeutic Options: A Workshop Report. Canadian Respiratory Journal, 2020, 2020, 1-16.	0.8	39

#	ARTICLE	IF	CITATIONS
55	Surfactant Lipidomics in Healthy Children and Childhood Interstitial Lung Disease. <i>PLoS ONE</i> , 2015, 10, e0117985.	1.1	38
56	Fatal neonatal respiratory failure in an infant with congenital hypothyroidism due to haploinsufficiency of the NKX2-1 gene: alteration of pulmonary surfactant homeostasis. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2011, 96, F453-F456.	1.4	36
57	Respiratory syncytial virus potentiates ABCA3 mutation-induced loss of lung epithelial cell differentiation. <i>Human Molecular Genetics</i> , 2012, 21, 2793-2806.	1.4	36
58	Heterozygous <i>OAS1</i> gain-of-function variants cause an autoinflammatory immunodeficiency. <i>Science Immunology</i> , 2021, 6, .	5.6	36
59	Oxidative stress in cystic fibrosis lung disease: an early event, but worth targeting?. <i>European Respiratory Journal</i> , 2014, 44, 17-19.	3.1	35
60	Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function. <i>American Journal of Human Genetics</i> , 2018, 103, 100-114.	2.6	34
61	Pulmonary alveolar proteinosis in children on La R�union Island: a new inherited disorder?. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 85.	1.2	33
62	Management of children with interstitial lung diseases: the difficult issue of acute exacerbations. <i>European Respiratory Journal</i> , 2016, 48, 1559-1563.	3.1	33
63	Functional rescue of misfolding ABCA3 mutations by small molecular correctors. <i>Human Molecular Genetics</i> , 2018, 27, 943-953.	1.4	33
64	Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 42.	1.2	33
65	Assessment of the multiplex PCR-based assay Unyvero pneumonia application for detection of bacterial pathogens and antibiotic resistance genes in children and neonates. <i>Infection</i> , 2018, 46, 189-196.	2.3	33
66	Oxidative damage to surfactant protein D in pulmonary diseases. <i>Free Radical Research</i> , 2006, 40, 419-425.	1.5	32
67	Whole-lung lavage in infants and children with pulmonary alveolar proteinosis. <i>Paediatric Anaesthesia</i> , 2010, 20, 1118-1123.	0.6	32
68	Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF). <i>BMC Pulmonary Medicine</i> , 2019, 19, 130.	0.8	32
69	Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. <i>Respiratory Research</i> , 2005, 6, 133.	1.4	31
70	Long-term follow-up and treatment of congenital alveolar proteinosis. <i>BMC Pediatrics</i> , 2011, 11, 72.	0.7	31
71	Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. <i>European Respiratory Journal</i> , 2012, 40, 1468-1474.	3.1	31
72	Long-Term Inhaled Granulocyte Macrophage Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose. <i>Clinical Drug Investigation</i> , 2014, 34, 553-564.	1.1	31

#	ARTICLE	IF	CITATIONS
73	Eradication of initial <i>Pseudomonas aeruginosa</i> colonization in patients with cystic fibrosis. <i>European Journal of Medical Research</i> , 2002, 7, 79-80.	0.9	31
74	Therapeutic lung lavages in children and adults. <i>Respiratory Research</i> , 2005, 6, 138.	1.4	30
75	The surfactant lipid transporter ABCA3 is N-terminally cleaved inside LAMP3-positive vesicles. <i>FEBS Letters</i> , 2010, 584, 4306-4312.	1.3	30
76	Research in progress: put the orphanage out of business: Table 1. <i>Thorax</i> , 2013, 68, 971-973.	2.7	28
77	Chitinase activation in patients with fungus-associated cystic fibrosis lung disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1183-1189.e4.	1.5	28
78	ABCA3 missense mutations causing surfactant dysfunction disorders have distinct cellular phenotypes. <i>Human Mutation</i> , 2018, 39, 841-850.	1.1	28
79	<i>SFTPC</i> mutations cause <i>SP</i> degradation and aggregate formation without increasing <i>ER</i> stress. <i>European Journal of Clinical Investigation</i> , 2013, 43, 791-800.	1.7	27
80	Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 1747.	1.0	27
81	The basidiomycetous yeast <i>Trichosporon</i> may cause severe lung exacerbation in cystic fibrosis patients – clinical analysis of <i>Trichosporon</i> -positive patients in a Munich cohort. <i>BMC Pulmonary Medicine</i> , 2013, 13, 61.	0.8	26
82	Potential of ABCA3 lipid transport function by ivacaftor and genistein. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 5225-5234.	1.6	26
83	Delivery of Alpha-1 Antitrypsin to Airways. <i>Annals of the American Thoracic Society</i> , 2016, 13, S346-S351.	1.5	25
84	Quantitative Lipidomics in Pulmonary Alveolar Proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 881-887.	2.5	25
85	Surfactant proteins SP-B and SP-C and their precursors in bronchoalveolar lavages from children with acute and chronic inflammatory airway disease. <i>BMC Pulmonary Medicine</i> , 2008, 8, 6.	0.8	24
86	Development and validation of a health-related quality of life questionnaire for pediatric patients with interstitial lung disease. <i>Pediatric Pulmonology</i> , 2018, 53, 954-963.	1.0	24
87	Elemental and ion composition of exhaled AIR condensate in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2003, 2, 136-142.	0.3	23
88	Surfactant proteins in pediatric interstitial lung disease. <i>Pediatric Research</i> , 2016, 79, 34-41.	1.1	23
89	Expression profiles of hydrophobic surfactant proteins in children with diffuse chronic lung disease. <i>Respiratory Research</i> , 2005, 6, 80.	1.4	22
90	Pulmonary alveolar proteinosis: time to shift?. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 337-349.	1.0	22

#	ARTICLE	IF	CITATIONS
91	Bi-allelic missense <i>ABCA3</i> mutations in a patient with childhood ILD who reached adulthood. ERJ Open Research, 2019, 5, 00066-2019.	1.1	22
92	Increased Risk of Interstitial Lung Disease in Children with a Single R288K Variant of ABCA3. Molecular Medicine, 2016, 22, 183-191.	1.9	21
93	A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. Chest, 2016, 150, 251-253.	0.4	20
94	Long-term pulmonary outcome after meconium ileus in cystic fibrosis. Pediatric Pulmonology, 2009, 44, 1201-1206.	1.0	19
95	A non-BRICHOS surfactant protein c mutation disrupts epithelial cell function and intercellular signaling. BMC Cell Biology, 2010, 11, 88.	3.0	19
96	The surfactant protein C mutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation. BMC Pulmonary Medicine, 2012, 12, 15.	0.8	19
97	Tools to explore ABCA3 mutations causing interstitial lung disease. Pediatric Pulmonology, 2016, 51, 1284-1294.	1.0	19
98	Early onset children's interstitial lung diseases: Discrete entities or manifestations of pulmonary dysmaturity?. Paediatric Respiratory Reviews, 2019, 30, 65-71.	1.2	19
99	Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic <i>MARS1</i> variants. Pediatric Pulmonology, 2020, 55, 3057-3066.	1.0	19
100	ABCA3 protects alveolar epithelial cells against free cholesterol induced cell death. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 987-995.	1.2	18
101	The chemokine CCL18 characterises <i>Pseudomonas</i> infections in cystic fibrosis lung disease. European Respiratory Journal, 2014, 44, 1608-1615.	3.1	16
102	Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE). PLoS ONE, 2016, 11, e0157789.	1.1	16
103	Quantification of volume and lipid filling of intracellular vesicles carrying the ABCA3 transporter. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 2330-2335.	1.9	16
104	Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: A registry-based case series. Pediatric Pulmonology, 2020, 55, 909-917.	1.0	16
105	<i>FARS1</i> -related disorders caused by bi-allelic mutations in cytosolic phenylalanyl-tRNA synthetase genes: Look beyond the lungs!. Clinical Genetics, 2021, 99, 789-801.	1.0	16
106	CYTOKINE STIMULATION BY PSEUDOMONAS AERUGINOSA STRAIN VARIATION AND MODULATION BY PULMONARY SURFACTANT. Experimental Lung Research, 2004, 30, 163-179.	0.5	15
107	Lung disease in STAT 3 hyper-IgE syndrome requires intense therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1691-1702.	2.7	15
108	Incidence and Prevalence of Children's Diffuse Lung Disease in Spain. Archivos De Bronconeumologia, 2022, 58, 22-29.	0.4	15

#	ARTICLE	IF	CITATIONS
109	Lavage lipidomics signatures in children with cystic fibrosis and protracted bacterial bronchitis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 790-795.	0.3	14
110	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. <i>ERJ Open Research</i> , 2021, 7, 00805-2020.	1.1	14
111	Deleted in Malignant Brain Tumors 1 (DMBT1) is present in hyaline membranes and modulates surface tension of surfactant. <i>Respiratory Research</i> , 2007, 8, 69.	1.4	12
112	Pulmonary function testing in children's interstitial lung disease. <i>European Respiratory Review</i> , 2020, 29, 200019.	3.0	12
113	Successful weaning from mechanical ventilation in a patient with surfactant protein C deficiency presenting with severe neonatal respiratory distress. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013203053-bcr2013203053.	0.2	12
114	Agglutination of <i>Pseudomonas aeruginosa</i> by Surfactant Protein D. <i>Pediatric Pulmonology</i> , 2005, 40, 378-384.	1.0	11
115	Increasing Total Serum IgE, Allergic Bronchopulmonary Aspergillosis, and Lung Function in Cystic Fibrosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1591-1598.e6.	2.0	11
116	One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD). <i>Thorax</i> , 2020, 75, 172-175.	2.7	11
117	Persistent tachypnea of infancy: Follow up at school age. <i>Pediatric Pulmonology</i> , 2020, 55, 3119-3125.	1.0	11
118	Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2608-2614.e3.	2.0	11
119	Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial. <i>Trials</i> , 2020, 21, 307.	0.7	11
120	Predictive values of antibodies against <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis one year after early eradication treatment. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 534-541.	0.3	10
121	CXCR4 ⁺ granulocytes reflect fungal cystic fibrosis lung disease. <i>European Respiratory Journal</i> , 2015, 46, 395-404.	3.1	10
122	Expanding the phenotypic spectrum of FINCA (fibrosis, neurodegeneration, and cerebral angiomatosis) syndrome beyond infancy. <i>Clinical Genetics</i> , 2021, 100, 453-461.	1.0	10
123	High-Content Screening Identifies Cyclosporin A as a Novel ABCA3-Specific Molecular Corrector. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 382-390.	1.4	10
124	Interstitial lung disease in infancy and early childhood: a clinicopathological primer. <i>European Respiratory Review</i> , 2022, 31, 210251.	3.0	10
125	Genetic testing in interstitial lung disease: An international survey. <i>Respirology</i> , 0, , .	1.3	10
126	Analysis of the Proteolytic Processing of ABCA3: Identification of Cleavage Site and Involved Proteases. <i>PLoS ONE</i> , 2016, 11, e0152594.	1.1	9

#	ARTICLE	IF	CITATIONS
127	Patient education for children with interstitial lung diseases and their caregivers: A pilot study. <i>Patient Education and Counseling</i> , 2019, 102, 1131-1139.	1.0	9
128	Early-onset, fatal interstitial lung disease in STAT3 gain-of-function patients. <i>Pediatric Pulmonology</i> , 2021, 56, 3934-3941.	1.0	9
129	Surfactant Protein A in Cystic Fibrosis: Supratrimeric Structure and Pulmonary Outcome. <i>PLoS ONE</i> , 2012, 7, e51050.	1.1	9
130	Case Report: Unilateral Sixth Cranial Nerve Palsy Associated With COVID-19 in a 2-year-old Child. <i>Frontiers in Pediatrics</i> , 2021, 9, 756014.	0.9	9
131	Skin Prick Test Reactivity to Supplemental Enzymes in Cystic Fibrosis and Pancreatic Insufficiency. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 194-198.	0.9	8
132	An informative intragenic microsatellite marker suggests the IL-1 receptor as a genetic modifier in cystic fibrosis. <i>European Respiratory Journal</i> , 2017, 50, 1700426.	3.1	8
133	Variation in the bombesin staining of pulmonary neuroendocrine cells in pediatric pulmonary disorders—a useful marker for airway maturity. <i>Pediatric Pulmonology</i> , 2020, 55, 2383-2388.	1.0	8
134	Pulmonary alveolar proteinosis in a cat. <i>BMC Veterinary Research</i> , 2015, 11, 302.	0.7	7
135	Adherence pattern to study drugs in clinical trials by patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2016, 51, 143-146.	1.0	7
136	Increasing sputum levels of gamma-glutamyltransferase may identify cystic fibrosis patients who do not benefit from inhaled glutathione. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 342-345.	0.3	7
137	Metabolic labelling of choline phospholipids probes ABCA3 transport in lamellar bodies. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2019, 1864, 158516.	1.2	7
138	Comorbidity and long-term clinical outcome of laryngotracheal clefts types III and IV: Systematic analysis of new cases. <i>Pediatric Pulmonology</i> , 2021, 56, 138-144.	1.0	7
139	Airways glutathione S-transferase omega-1 and its A140D polymorphism are associated with severity of inflammation and respiratory dysfunction in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1053-1061.	0.3	6
140	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 577263.	1.6	6
141	Assessment of Surfactant Protein A (SP-A) dependent agglutination. <i>BMC Pulmonary Medicine</i> , 2010, 10, 59.	0.8	5
142	Life-threatening, giant pneumatoceles in the course of surfactant protein C deficiency. <i>Pediatric Pulmonology</i> , 2015, 50, E25-8.	1.0	5
143	Pott's disease: a major issue for an unaccompanied refugee minor. <i>Thorax</i> , 2017, 72, 282-283.	2.7	5
144	Pulmonary alveolar proteinosis due to heterozygous mutation in <i>OAS1</i> : Whole lung lavages for long-term bridging to hematopoietic stem cell transplantation. <i>Pediatric Pulmonology</i> , 2022, 57, 273-277.	1.0	5

#	ARTICLE	IF	CITATIONS
145	Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe. <i>Thorax</i> , 2022, 77, 781-789.	2.7	5
146	Acute exacerbations in children's interstitial lung disease. <i>Thorax</i> , 2022, 77, 799-804.	2.7	5
147	Lung ultrasound—a new diagnostic modality in persistent tachypnea of infancy. <i>Pediatric Pulmonology</i> , 2020, 55, 1028-1036.	1.0	4
148	The improved clinical course of persistent tachypnea of infancy with inhaled bronchodilators and corticosteroids. <i>Pediatric Pulmonology</i> , 2021, 56, 3952-3959.	1.0	4
149	Exhaled breath condensate. <i>Pediatric Pulmonology</i> , 2004, 37, 14-15.	1.0	3
150	Respiratory Bronchiolitis-Associated Interstitial Lung Disease in Childhood: New Sequela of Smoking. <i>Pediatrics</i> , 2015, 136, e1026-e1029.	1.0	3
151	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. <i>European Respiratory Journal</i> , 2016, 48, 282-283.	3.1	3
152	Homooligomerization of ABCA3 and its functional significance. <i>International Journal of Molecular Medicine</i> , 2016, 38, 558-566.	1.8	3
153	Hypersensitivity pneumonitis: Lessons from a randomized controlled trial in children. <i>Pediatric Pulmonology</i> , 2021, 56, 2627-2633.	1.0	3
154	Cibacron blue stimulation of surfactant secretion in rat type II pneumocytes. <i>British Journal of Pharmacology</i> , 1992, 106, 373-379.	2.7	2
155	Uptake of a natural surfactant and increased delivery of small organic anions into type II pneumocytes. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001, 281, L144-L154.	1.3	2
156	Pulmonary Hypertension Presenting With Apnea, Cyanosis, and Failure to Thrive in a Young Child. <i>Chest</i> , 2011, 140, 1086-1089.	0.4	2
157	Pushing chILD Forward: The Bright Future of Children's Interstitial Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1428-1429.	1.5	2
158	Cardiovascular risk in pulmonary alveolar proteinosis. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 235-240.	1.0	2
159	Abandoning developmental silos. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 418-425.	1.2	2
160	Autoimmune PAP (aPAP) in children. <i>ERJ Open Research</i> , 2022, 8, 00701-2021.	1.1	2
161	Meconium ileus—it is time to act now!. <i>Pediatric Pulmonology</i> , 2010, 45, 949-950.	1.0	1
162	Do Not Miss Acute Diffuse Panbronchiolitis for Tree-in-Bud: Case Series of a Rare Lung Disease. <i>Diagnostics</i> , 2022, 12, 1653.	1.3	1

#	ARTICLE	IF	CITATIONS
163	Surfactant dysfunction syndromes and pulmonary alveolar proteinosis. , 2021, , 602-609.		0
164	Sonstige Lungenerkrankungen. , 2014, , 773-786.		0
165	Zystische Fibrose. , 2014, , 795-818.		0
166	Spezielle interstitielle Lungenerkrankungen im Kindesalter. , 2016, , 283-296.		0